TCTR20240401001招募中不适用
Immunoprophylactic failure against hepatitis B virus mother to infant transmission from 2018 to 2023
/A0 个研究点目标入组 500 人开始时间: 2024年4月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 1 Hours 至 6 Months（—）
- 性别
- All
入选标准
- •All children of hepatitis B surface antigen (HBsAg) seropositive mothers with known HBeAg status
排除标准
- •children of hepatitis B surface antigen (HBsAg) seropositive mothers with unknown HBeAg status
研究者
相似试验
进行中（未招募）
1 期
Prevention of re-onset of HBV infection in patients apparently cured affected by rheumatological diseases requiring finite duration treatments with drugs that impair the immune systems.EUCTR2015-000570-35-ITDIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II40
已完成
不适用
Immune response to hepatitis B vaccine among HIV positive patientsCondition 1: chronic hepatitis B. Condition 2: Human Immunodeficeincy Virus.Chronic viral hepatitis B without delta-agent Chronic (viral) hepatitis BHIV disease resulting in haematological and immunological abnormalities, not elsewhere classifiedIRCT2015072023251N1Vice Chancellor of Hamadan University of Medical Sciences30
尚未招募
不适用
Immunogenic response in children with hemophilia to Hepatitis B vaccine administered by subcutaneous versus intradermal route.CTRI/2019/12/022528niversity College of Medical Sciences and Guru Teg Bahadur Hospital
已完成
4 期
Immunological response to Hepatitis B vaccination in obsessive compulsive disorder patients receiving high doses of serotonin reuptake inhibitorsdrug-induced immunosuppression1002766510002861NL-OMON38586Academisch Medisch Centrum20
进行中（未招募）
1 期
ong-term persistence of immunity to hepatitis B in adults vaccinated with GlaxoSmithKline (GSK) Biologicals’ hepatitis B vaccine (HBV), Engerix™-B.Healthy volunteers (immunisation against infection caused by all known subtypes of hepatitis B virus).MedDRA version: 19.0Level: PTClassification code 10019731Term: Hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-004099-31-BEGlaxosmithkline Biologicals100